Drug

Soquelitinib clinical trials

Also written CPI-818.

studies test it: 6
open now: 4
in phase 3: 1
first study started: 2019

How each study uses soquelitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the soquelitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Soquelitinib: 5

Development codes

CPI-818: 5

Studies by the year they started

6 studies that test it; most in 2024 (2)

Studies that test soquelitinib, by start year
Year	Studies
2019	1
2024	2
2025	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 2
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, T-Cell: 2
Dermatitis, Atopic: 2
Hidradenitis Suppurativa: 1

Who runs them

Industry 5 · Other 1

Corvus Pharmaceuticals, Inc. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test soquelitinib, phase 3 first.

Nov 2027Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPhase 3 · Corvus Pharmaceuticals, Inc.
Dec 2026Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS PatientsPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
Dec 2026A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaPhase 1 · Corvus Pharmaceuticals, Inc.
Jun 2027Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADPhase 2 · Corvus Pharmaceuticals, Inc.

Studies

Open first, then newest update. How each study uses soquelitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 6

Codes

What other systems call soquelitinib · ClinicalTrials.gg INT015279

UNII (FDA) 6I5H17AN3ISOQUELITINIBOne source FDA
NCI Thesaurus C162010SoquelitinibOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	6I5H17AN3I	SOQUELITINIB	One source FDA
NCI Thesaurus	C162010	Soquelitinib	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.